Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
Articles Healthcare systems aren’t making the most of biosimilars: ph... Biosimilars could save European and US healthcare systems billions - but more needs to be done to maximise their benefits, writes Richard Staines.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
